Results 71 to 80 of about 1,362,061 (313)

Convocatoria simposio 2015 / Call for Papers Symposium 2015

open access: yesBolivian Studies Journal, 2014
Convocatoria simposio 2015 / Call for Papers Symposium ...
. .
doaj   +1 more source

UA68/2 Intercambio Internacional, Vol. X, No. 2 [PDF]

open access: yes, 1988
Newsletter created by WKU Latin American Studies program regarding science, politics and economic advances in Latin America as well as cooperative projects between WKU and universities across Latin America.
WKU Latin American Studies
core   +1 more source

Inside Civil Society in Mexico: The RGK Center Partnership [PDF]

open access: yes, 2007
Latin American ...
Frumkin, Peter, Smith, Steven C.
core   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Bolivia Reader

open access: yesBolivian Studies Journal, 2018
.
. .
doaj   +1 more source

[Review of] Raymond T. Smith, ed. Kinship Ideology and Practice in Latin America [PDF]

open access: yes, 1986
Kinship Ideology and Practice in Latin America is a collection of papers resulting from two conferences sponsored by the Joint Committee on Latin American Studies of the American Council of Learned Societies and the Social Science Research Council.
Whiteford, Michael B.
core   +1 more source

LLILAS Benson News [PDF]

open access: yes, 2015
Latin American ...
LLILAS staff
core   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy